Supernus Pharmaceuticals President and CEO Jack A. Khattar filed a Form 4 on November 2, 2026, disclosing the acquisition of 400,000 restricted stock units on October 30, 2026, with vesting tied to the closing of a planned merger with Indivior Pharmaceuticals, Inc.

Key Highlights

  • Reporting person: Jack A. Khattar, President and CEO and Director of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
  • Transaction date: October 30, 2026; transaction code A (acquisition)
  • Award size: 400,000 restricted stock units (RSUs) acquired at a price of $0
  • Post-transaction holdings: 400,000 derivative securities beneficially owned directly following the reported transaction
  • Vesting schedule: 50% at the closing of the Supernus-Indivior merger-of-equals, then 15% at one-year, 15% at two-year, and 20% at three-year anniversaries of that closing
  • Settlement: RSUs are settled in common stock upon vesting

Khattar RSU Grant Details and Merger-Linked Vesting Structure

According to the filing, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) President and CEO Jack A. Khattar received a grant of 400,000 restricted stock units on October 30, 2026. The RSUs were acquired at a stated price of $0 and are classified as direct holdings. The underlying security is common stock of Supernus Pharmaceuticals, Inc., and each RSU represents one share upon settlement.

The filing discloses an unusual vesting structure linked to a corporate transaction. Specifically, the filing states that the RSUs "are settled in common stock upon vesting, which occurs in four installments." The first installment, covering 50% of the RSUs, vests upon the closing of what the filing describes as "the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc." The remaining installments vest at one-year (15%), two-year (15%), and three-year (20%) anniversaries of that closing date. The filing does not provide a date for the anticipated closing of the merger.

The Form 4 was signed by Timothy C. Dec as attorney-in-fact for Khattar and filed on November 2, 2026. No transactions were reported in Table I covering non-derivative securities. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) trading plan.

What Was Disclosed

The filing reports that Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, acquired 400,000 RSUs on October 30, 2026, at $0, with vesting contingent on the closing of a described merger-of-equals with Indivior Pharmaceuticals, Inc., and subsequent anniversaries thereof.